Abstract
Background
Nonalcoholic fatty liver disease (NAFLD) is common in adults with extreme obesity and can impact long-term health and survival. Liver biopsy is the only accurate test for diagnosis and staging, but is invasive and costly. Non-invasive testing offers an attractive alternate, but the overall accuracy remains a significant issue. This study was conducted to determine the accuracy and clinical utility of pre-operative ultrasound and liver transaminase levels, as well as intra-operative hepatic visual inspection, for assessing presence of NAFLD as confirmed by hepatic histology.
Methods
Data was collected prospectively from 580 morbidly obese adult patients who underwent Roux-en-Y gastric bypass surgery with intraoperative wedge biopsy between January 2004 and February 2009. Complete data for ultrasound, ALT and AST levels, and documented visual inspection was available for 513 patients.
Results
The prevalence of NAFLD was 69 % and that of NASH was 32 %. The individual non-invasive clinical assessments demonstrated low sensitivity, specificity, and accuracy for detecting the presence of steatosis, steatohepatitis, or fibrosis. The combination of normal or abnormal results for all tests improved predictive utility. Abnormal tests with all three assessments had a sensitivity of 95–98 % and a specificity of 28–48 % for major histologic findings in NAFLD/NASH. Normal tests with all three assessments had a sensitivity of 12–22 % and a specificity of 89–97 % for major histologic findings in NAFLD/NASH.
Conclusions
Although individual clinical tests for NAFLD have limited accuracy, the use of combined clinical tests may prove useful.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.References
Barsic N, Lerotic I, Smircic-Duvnjak L, et al. Overview and developments in noninvasive diagnosis of non-alcoholic fatty liver disease. World J Gastroenterol. 2012;18(30):3945–54. doi:10.3748/wjg.v18.i30.3945.
Vernon G, Baranova A, Younossi M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–85. doi:10.1111/j.1365-2036.2011.04724.x.
Pais R, Pascale A, Fedchuck L, et al. Progression from isolated steatosis to steatohepatitis and fibrosis in non-alcoholic fatty liver disease. Clin Res Hepatol Gastroenterol. 2011;35(1):23–8.
Wong V, Wong G, Choi P, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59(7):969–74. doi:10.1136/gut.2009.205088.
Ekstedt M, Franz L, Mathiesen U, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865–73.
Soderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51(2):595–602. doi:10.1002/hep.23314.
Marceau P, Biron S, Hould F, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84(5):1513–7.
Chalasani N, Younossi Z, Lavine J, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guidelines by the American gastroenterological association, American association for the study of liver diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592–609. doi:10.1053/j.gastro.2012.04.001.
Williams C, Stengel J, Asike M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged populatin utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–31. doi:10.1053/j.gastro.2010.09.038.
Boza C, Riquelme A, Ibnez L, et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg. 2005;15(8):1148–53.
Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45(4):600–6.
Abrams G, Kundle S, Lazenby A, et al. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology. 2004;40(2):475–83.
Kral J, Schaffner F, Pierson R, et al. Body fat topography as an independent predictor of fatty liver. Metabolism. 1993;42(5):548–51.
Jakobsen M, Berentzen T, Sorensen T, et al. Abdominal obesity and fatty liver. Epidemiol Rev. 2007;29:77–87.
Denzer U, Luth S. Non-invasive diagnosis and monitoring of liver fibrosis and cirrhosis. Best Pract Res Clin Gastroenterol. 2009;23(3):453–60. doi:10.1016/j.bpg.2009.03.002.
Miele L, Forgione A, Gasbarrini G, et al. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res. 2007;149(3):114–25.
Pearce S, Thosani N, Pan J. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res. 2013;1(1):7. doi:10.1186/2050-7771-1-7.
Dolce C, Russo M, Keller J, et al. Does liver appearance predict histopathologic findings: prospective analysis of routine liver biopsies during laparoscopic bariatric surgery. Surg Obes Relat Dis. 2009;5(3):323–8. doi:10.1016/j.soard.2008.12.008.
Brunt E, Janney C, Di Bisceglie A, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94(9):2467–74.
Saverymuttu S, Joseph A, Maxwell J. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed). 1986;292(6512):13–5.
Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102(12):2708–15.
Marceau P, Biron S, Hould F, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84(5):1513–7.
Dixon J, Bhathal P, O’Brien P. Nonalcoholic fatty liver disease: predictors of non-alcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121(1):91–100.
Abrams G, Kunde S, Lazenby A, et al. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology. 2004;40(2):475–83.
Kallwitz E, Guzman G, TenCate V, et al. The histologic spectrum of liver disease in African-American, non-Hispanic White, and Hispanic obesity surgery patients. Am J Gastroenterol. 2009;104(1):64–9. doi:10.1038/ajg.2008.12.
Kroh M, Liu R, Chand B. Laparoscopic bariatric surgery: what else are we uncovering? Liver pathology and preoperative indicators of advanced liver disease in morbidly obese patients. Surg Endosc. 2007;21(11):1957–60.
Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56(5):1751–9. doi:10.1002/hep.25889.
Ong J, Eariny H, Collantes R, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg. 2005;15(3):310–5.
Abrams G, Kunde S, Lazenby A, et al. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology. 2004;40(2):475–83.
Mofrad P, Contos M, Haque M, et al. Clinical and histological spectrum of nonalcoholic fatty liver disease associated with normal ALT levels. Hepatology. 2003;37(6):1286–92.
Pearce S, Thosani N, Pan J. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res. 2013;1(1):7. doi:10.1186/2050-7771-1-7.
Liang R, Wang H, Lee W, et al. Diagnostic value of ultrasonographic examination for nonalcoholic steatohepatitis in morbidly obese patients undergoing laparoscopic bariatric surgery. Obes Surg. 2007;17(1):45–56.
de Moura A, Cotrim H, Barbosa D, et al. Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound. World J Gastroenterol. 2008;14(9):1415–8.
Helling T, Helzberg J, Nachnani J, et al. Predictors of nonalcoholic steatohepatitis in patients undergoing bariatric surgery: when is liver biopsy indicated? Surg Obes Relat Dis. 2008;4(5):612–7. doi:10.1016/j.soard.2007.11.007.
Dolce C, Russo M, Keller J, et al. Does liver appearance predict histopathologic findings: prospective analysis of routine liver biopsies during bariatric surgery? Surg Obes Relat Dis. 2009;5(3):323–8. doi:10.1016/j.soard.2008.12.008.
Angulo P, Hui J, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–54.
Acknowledgments
This work was supported by funding from the National Institutes of Health grants DK091601, DK088231, P30 DK072488, and the Geisinger Obesity Institute.
Conflict of Interest
The authors declare that they have no competing interest.
Statement of Informed Consent
Informed consent was obtained from all individual participants included in this study.
Statement of Human and Animal Rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Petrick, A., Benotti, P., Wood, G.C. et al. Utility of Ultrasound, Transaminases, and Visual Inspection to Assess Nonalcoholic Fatty Liver Disease in Bariatric Surgery Patients. OBES SURG 25, 2368–2375 (2015). https://doi.org/10.1007/s11695-015-1707-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11695-015-1707-6